Adjuvant Immunotherapy After Lung Cancer Surgery — Who Needs It, and For How Long

Only a small group. Most lung cancers in India are found too late for surgery at all, and among the tumours that are removed, adjuvant immunotherapy is limited by the stage after surgery, by the biomarker report and by recovery. It is considered for resected non-small cell lung cancer, usually after platinum-based chemotherapy — not for everyone who has had an operation.

This is said first, and plainly, because the adjuvant question reaches far more families than it applies to. Lung cancer is the largest immunotherapy population in India by volume, and much of what is written about it describes advanced disease, where the rules are completely different. Being told after surgery that immunotherapy exists is not the same as being told it applies to you. At CION the eligibility question goes to the tumour board with the operation notes, the surgical pathology and the biomarker report in front of it, before any plan is put to the family.

Criteria as set out in NCCN and ESMO non-small cell lung cancer guidance. Regulatory approvals differ between countries, and what may be prescribed in India is governed by CDSCO labelling — confirm with your oncologist which criteria apply to the product being offered to you. If surgery was not possible in your case, the equivalent question is covered on our page about consolidation immunotherapy after chemoradiation.

About a year. Infusions are given as day care, most often every three weeks or every four weeks depending on the schedule chosen, with no overnight stay. It starts after adjuvant chemotherapy has finished, not alongside it. Treatment stops earlier if imaging shows the cancer has returned, or if a side effect makes continuing unsafe.

Schedule and duration as described in NCCN and ESMO guidance for resected non-small cell lung cancer. The interval and the total duration vary with the product selected — ask for your own schedule and your planned end date in writing before the first cycle.

It aims to lower the chance the cancer comes back. That is the whole claim. It does not act on anything visible, because after a complete resection the scan is clear. The size of the benefit differs by stage and by biomarker, and it is a reduction in risk across a group rather than a promise to one person.

This is the part families find hardest, and it deserves to be said out loud. You are being asked to take a year of treatment at the point where you feel better than you have in months. The operation is behind you. The scan is clear. Nothing hurts. And the treatment being proposed will cost money, take time, and carry real side effects, in exchange for a benefit you will never be able to see happen.

What the benefit is, and what it is not:

• It is a reduction in risk, not a removal of risk — some people who take it will still have a recurrence, and some who decline it never would have had one.
• It is measured across a group, not promised to an individual — nobody can tell you in advance which side of that you will fall on.
• It depends heavily on your stage and your biomarker report — the same treatment is a much weaker proposition for early node-negative disease than for higher-stage resected disease.
• Long-term follow-up is still maturing for several of these indications, and guideline bodies state that openly rather than glossing over it.
• It does not replace surveillance — scans and follow-up continue either way, treated or not.
• Choosing not to have it is a real option — surveillance after a complete resection is a recognised path, not a refusal of care.

A page cannot make this decision for you, and this one is not trying to. What you are owed is the reasoning, the timeline and the cost in language you can repeat at home to the people who will help you decide. That is what a 45-minute consultation and a tumour board review are for. If anyone tells you this treatment removes the risk of the cancer returning, or refuses to explain what happens if you decline, ask for a second opinion before you sign anything.

Three results do most of the work: the stage confirmed after surgery, the PD-L1 result, and whether the tumour carries an EGFR or ALK alteration. All three come from tissue the operation already removed. If any of them is missing from your file, ask whether it can still be run on the stored block.

Biomarker-led pathways as set out in NCCN and ESMO non-small cell lung cancer guidance; Indian prescribing is governed by CDSCO labelling. Your own report may use different wording — bring it to the consultation rather than relying on a summary of it.

Anything new, and breathing above everything else. You are being treated at a time when you feel well, which makes a new symptom very easy to dismiss. New or worsening breathlessness, a new dry cough, loose motions several times a day, or fever should be reported the same day.

Call 1800 202 8726 the same day if any of the following start or get worse. Do not wait for the next scheduled cycle, and do not start or stop steroids on your own.

• Breathlessness that is new, or worse than last week — compare with last week, not with how you breathed before the operation.
• A new dry cough, or a clear change in a cough you already had.
• Loose motions several times a day, or blood or mucus in the stool.
• Fever, with or without a cough.
• Chest pain or a racing heartbeat — go to the nearest emergency department now, and tell them you are on immunotherapy.
• Deep tiredness, dizziness or feeling faint — these can be the first sign of a thyroid or adrenal problem.

Immune-related effects do not follow the chemotherapy timetable families are used to. They can appear weeks or months into treatment, and occasionally after it has finished. Part of a lung has been removed, so your baseline is already different — which is why the comparison to make is with last week, not with last year. Carry a card or a note saying you are on, or have recently completed, immunotherapy, and show it at any hospital you attend, including for something that seems unrelated. This one habit changes how quickly the right treatment gets started.

The infusion is the largest line in the bill, and it repeats across roughly a year. Scans, blood tests and day-care charges sit on top of it. All figures are indicative, as of August 2026, and move with the product selected, biosimilar availability, the centre and your scheme cover.

What actually drives the total:

• How many cycles you complete — a twelve-month plan is priced per cycle, not as one lump sum, and it can stop earlier.
• The dosing interval — a three-weekly and a four-weekly schedule do not cost the same across a year, even for the same treatment.
• Whether a biosimilar option exists for the product your oncologist selects at the time you start.
• Scans and blood tests — surveillance imaging is coordinated for you at partner imaging centres and quoted before the appointment.
• Scheme and insurance cover — Aarogyasri, CGHS, ECHS, ESI and private insurance each treat the adjuvant setting differently, and ceilings change.

Six questions worth asking before you agree:

• What is my stage after surgery? Ask for the pathological stage from the specimen, not the stage that was assumed beforehand.
• Does that stage place me in the adjuvant group at all? For the earliest node-negative disease, the honest answer is often no.
• What is my PD-L1 result, and is a threshold being applied to me? Ask for the answer in writing, since this rule differs by product.
• Were EGFR and ALK tested, and what did they show? If they were not tested, ask for testing on the stored block first.
• What is my planned end date, and what is the cost up to it? Include scans, blood tests and the possibility of an admission.
• What happens if I choose surveillance instead? You are entitled to hear that option described properly, not dismissed.

If you are the family member coordinating all of this, the most useful thing you can carry is one folder: the operation notes, the surgical pathology report, the biomarker report, the chemotherapy record, the latest scan and the current medication list including steroid doses. That folder is what a second opinion actually runs on.

The same question — treat after surgery, or watch — is asked in other cancers too, and melanoma is where the adjuvant conversation is furthest developed. These pages cover that version of the decision, and where to go if surgery was never possible.

• Adjuvant Immunotherapy After Melanoma Surgery — the same trade-off in the cancer where it was first established: a year of treatment against a risk you cannot see.
• Dual Immunotherapy for Melanoma: Higher Benefit, Higher Risk — useful for understanding how added benefit and added toxicity are weighed against each other.
• Acral and Mucosal Melanoma in India: Does Immunotherapy Work? — a clear example of why results from one population do not transfer automatically to another.
• How Long Does Adjuvant Immunotherapy Continue? — the duration question across cancers, and why twelve months keeps recurring.
• Consolidation Immunotherapy for Stage 3 Lung Cancer — the parallel pathway when the tumour could not be operated on.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, given as day care and monitored across our centres.

Ask What Happens If You Say No

Surveillance after a complete resection is a real option, and it should be explained to you properly rather than treated as giving up.